Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191,150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL. Adams EJ, et al. Among authors: liu y, liu d. Nature. 2019 Jul;571(7765):408-412. doi: 10.1038/s41586-019-1318-9. Epub 2019 Jun 26. Nature. 2019. PMID: 31243370 Free PMC article.
Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
Alshalalfa M, Liu Y, Wyatt AW, Gibb EA, Tsai HK, Erho N, Lehrer J, Takhar M, Ramnarine VR, Collins CC, Den RB, Schaeffer EM, Davicioni E, Lotan TL, Bismar TA. Alshalalfa M, et al. Among authors: liu y. Int J Cancer. 2019 Dec 15;145(12):3453-3461. doi: 10.1002/ijc.32430. Epub 2019 Jun 10. Int J Cancer. 2019. PMID: 31125117 Free PMC article.
Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.
Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. Zhao SG, et al. Among authors: liu y. Clin Cancer Res. 2019 Apr 15;25(8):2450-2457. doi: 10.1158/1078-0432.CCR-18-3121. Epub 2018 Dec 20. Clin Cancer Res. 2019. PMID: 30573691
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. Efstathiou JA, et al. Among authors: liu y. Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1. Eur Urol. 2019. PMID: 30712971 Free PMC article.
Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V, Kollár A, Vandekerkhove G, Blarer J, Furrer M, Annala M, Herberts C, Pycha A, de Jong JJ, Liu Y, Krentel F, Davicioni E, Gibb EA, Kruithof-de Julio M, Wyatt AW, Seiler R. Genitsch V, et al. Among authors: liu y. Urol Oncol. 2019 Nov;37(11):826-836. doi: 10.1016/j.urolonc.2019.09.025. Epub 2019 Oct 1. Urol Oncol. 2019. PMID: 31585777
Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.
Van den Broeck T, Moris L, Gevaert T, Tosco L, Smeets E, Fishbane N, Liu Y, Helsen C, Margrave J, Buerki C, Davicioni E, Van Poppel H, Everaerts W, Weinmann S, Den R, Davis J, Schaeffer E, Karnes RJ, Claessens F, Joniau S. Van den Broeck T, et al. Among authors: liu y. Eur Urol Oncol. 2019 Sep;2(5):589-596. doi: 10.1016/j.euo.2018.12.007. Epub 2019 Jan 11. Eur Urol Oncol. 2019. PMID: 31411980
Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V, Kollár A, Vandekerkhove G, Blarer J, Furrer M, Annala M, Herberts C, Pycha A, de Jong JJ, Liu Y, Krentel F, Davicioni E, Gibb EA, Kruithof-de Julio M, Wyatt AW, Seiler R. Genitsch V, et al. Among authors: liu y. Urol Oncol. 2019 Sep;37(9):573.e19-573.e29. doi: 10.1016/j.urolonc.2019.06.021. Epub 2019 Jul 26. Urol Oncol. 2019. PMID: 31358384
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. Zhao SG, et al. Among authors: liu y. J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141. J Natl Cancer Inst. 2019. PMID: 30321406
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.
Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM. Spratt DE, et al. Among authors: liu y. Clin Cancer Res. 2019 Nov 15;25(22):6721-6730. doi: 10.1158/1078-0432.CCR-19-1587. Epub 2019 Sep 12. Clin Cancer Res. 2019. PMID: 31515456 Free PMC article.
191,150 results
You have reached the last available page of results. Please see the User Guide for more information.